The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper

Saved in:

Bibliographic Details
Main Authors:	Faical Jarraya, Abdou Niang, Hussein Bagha, Elliot Koranteng Tannor, Ernest Kiswaya Sumaili, Davy Ip Min Wan, Mogamat-Yazied Chothia, Yewondwossen Tadesse Mengistu, Francois Folefack Kaze, Ifeoma Isabella Ulasi, Saraladevi Naicker, Mohamed Hany Hafez, Kouame Hubert Yao
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Kidney International Reports
Subjects:	Africa chronic kidney disease CKD management diabetic kidney disease SGLT2i sodium-glucose cotransporter-2 inhibitors
Online Access:	http://www.sciencedirect.com/science/article/pii/S246802492301642X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter‐2 inhibition in experimental rats
by: Ellen Wu, et al.
Published: (2025-07-01)

Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2025-05-01)

Sodium-glucose cotransporter 2 inhibitor for the treatment of diabetic nephropathy
by: Kong Ling-li, et al.
Published: (2021-01-01)

Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Stage 4 Cardiovascular–Kidney–Metabolic Syndrome: A Propensity Score–Matched Study
by: Tao Liu, et al.
Published: (2025-08-01)

Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers
by: Sul A. Lee, et al.
Published: (2024-06-01)

Sodium Chloride Cotransporter in Hypertension
by: Annalisa Castagna, et al.
Published: (2024-11-01)

Peroxiredoxin 5 Acts as a Negative Regulator of the Sodium-Chloride Cotransporter Involved in Alleviating Angiotensin II-Induced Hypertension
by: Hoon-In Choi, et al.
Published: (2025-01-01)

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)

SODIUM-POTASSIUM-CHLORIDE COTRANSPORT IN THE REGULATION OF VASCULAR MYOGENIC TONE
by: S. N. Orlov, et al.
Published: (2014-12-01)

Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors
by: L. V. Kremneva, et al.
Published: (2023-12-01)

Sodium–glucose cotransporter 2 inhibitors ameliorate glutathione cysteine ligase modifier-mediated oxidative stress and subsequent ferroptosis in proximal tubules of diabetic kidney disease
by: Yi-Chun Tsai, et al.
Published: (2025-12-01)

Mechanisms of acute renal injury caused by SGLT-2 inhibitor in patients with diabetes mellitus
by: Gong Yan, et al.
Published: (2021-01-01)

Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
by: E. R. Radkevich, et al.
Published: (2025-05-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Prevention of Adverse Kidney Outcomes in Type 2 Diabetes: A Clinical Multiethnic Asian Cohort
by: Liang Feng, et al.
Published: (2025-03-01)

Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
by: Lucie Maigret, et al.
Published: (2025-03-01)

Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study
by: Jeong-Hoon Lim, et al.
Published: (2024-08-01)

Perioperative euglycemic DKA: The YIN and YANG of sodium-glucose cotransporter 2 inhibitors
by: Shilpushp Bhosale, et al.
Published: (2025-01-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)

Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study
by: Min Wang, et al.
Published: (2025-07-01)

Effect of sodium-glucose cotransporter-2 inhibitor on metabolic syndrome in people with prediabetes and obesity: A systematic review and meta-analysis
by: Sadia Bari, et al.
Published: (2025-06-01)

Association of hyperkalaemia with electrocardiographic changes at a tertiary centre in South Africa
by: Francis R. Ssenabulya, et al.
Published: (2025-04-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)

Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01)

Early Initiation of Sodium–Glucose Cotransporter 2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta‐Analysis
by: Miloud Cherbi, et al.
Published: (2025-04-01)

Budget Impact and Cost–Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand
by: Arunmanakul P, et al.
Published: (2025-02-01)

Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
by: Wenfeng Wang, et al.
Published: (2025-06-01)

Genomic insights about the effect of sodium-glucose cotransporter 2 inhibitors: a systematic review
by: Pavitraa Saravana Kumar, et al.
Published: (2025-05-01)

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
by: Kiyotaka Uchiyama, et al.
Published: (2025-04-01)

Mind the Gap in Kidney Care: Translating What We Know into What We Do
by: Valerie A. Luyckx, et al.
Published: (2024-06-01)

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01)

Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes
by: Alessandro Colletta, et al.
Published: (2025-05-01)

Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
by: Sangmo Hong, et al.
Published: (2025-07-01)

Management of comorbid patients with chronic kidney disease and decline in renal function: a case report
by: A. I. Listratov, et al.
Published: (2024-10-01)

Refractory Arterial Hypertension: Features of Neurohormonal and Water-salt Imbalanceand Approaches to Antihypertensive Drug Therapy
by: O. B. Kuzmin, et al.
Published: (2022-09-01)

A case of pyelonephritis and bacteremia caused by Candida glabrata in a patient on sodium glucose cotransporter 2 inhibitor, successfully treated with micafungin
by: Shoko Sahara, et al.
Published: (2025-08-01)

Ocular outcomes of the sodium-glucose cotransport inhibitors: A systematic review of cohort studies
by: Nathaniel Eraikhuemen, et al.
Published: (2025-04-01)

Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
by: Nicia I. Profili, et al.
Published: (2025-03-01)

Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
by: Go Anan, et al.
Published: (2023-11-01)

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes
by: Xie H, et al.
Published: (2024-11-01)